{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:09:41Z","timestamp":1791083381445,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"DOI":"10.1038\/s41435-024-00278-3","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T10:02:27Z","timestamp":1716976947000},"page":"219-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Machine learning-derived immunosenescence index for predicting outcome and drug sensitivity in patients with skin cutaneous melanoma"],"prefix":"10.1038","volume":"25","author":[{"given":"Linyu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7484-153X","authenticated-orcid":false,"given":"Shaolong","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"278_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"278_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402:485\u2013502.","journal-title":"Lancet"},{"key":"278_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"278_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660\u201370.","journal-title":"Nat Immunol"},{"key":"278_CR5","doi-asserted-by":"publisher","first-page":"1980315","DOI":"10.1080\/21645515.2021.1980315","volume":"18","author":"R Marconcini","year":"2022","unstructured":"Marconcini R, Pezzicoli G, Stucci LS, Sergi MC, Lospalluti L, Porta C, et al. Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. Hum Vaccines Immunotherapeutics. 2022;18:1980315.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"278_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jjco\/hyab022","volume":"51","author":"D Ogata","year":"2021","unstructured":"Ogata D, Namikawa K, Takahashi A, Yamazaki N. A review of the AJCC melanoma staging system in the TNM classification (eighth edition). Jpn J Clin Oncol. 2021;51:671\u20134.","journal-title":"Jpn J Clin Oncol"},{"key":"278_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8:200.","journal-title":"Signal Transduct Target Ther"},{"key":"278_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","volume":"13","author":"J Lian","year":"2020","unstructured":"Lian J, Yue Y, Yu W, Zhang Y. Immunosenescence: a key player in cancer development. J Hematol Oncol. 2020;13:151.","journal-title":"J Hematol Oncol"},{"key":"278_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14737140.2022.2098718","volume":"22","author":"JE Rodriguez","year":"2022","unstructured":"Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, et al. Immunosenescence, inflammaging, and cancer immunotherapy efficacy. Expert Rev anticancer Ther. 2022;22:915\u201326.","journal-title":"Expert Rev anticancer Ther"},{"key":"278_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1172\/JCI133679","volume":"130","author":"X Liu","year":"2020","unstructured":"Liu X, Hoft DF, Peng G. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. J Clin Investig. 2020;130:1073\u201383.","journal-title":"J Clin Investig"},{"key":"278_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27\u201341.","journal-title":"Immunity"},{"key":"278_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1261\/rna.074922.120","volume":"26","author":"S Zhao","year":"2020","unstructured":"Zhao S, Ye Z, Stanton R. Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. RNA. 2020;26:903\u20139.","journal-title":"RNA"},{"key":"278_CR13","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/bioinformatics\/btu375","volume":"30","author":"HS Parker","year":"2014","unstructured":"Parker HS, Leek JT, Favorov AV, Considine M, Xia X, Chavan S, et al. Preserving biological heterogeneity with a permuted surrogate variable analysis for genomics batch correction. Bioinformatics. 2014;30:2757\u201363.","journal-title":"Bioinformatics"},{"key":"278_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"278_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"278_CR16","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"278_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017;18:248\u201362.","journal-title":"Cell Rep"},{"key":"278_CR18","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847\u20139.","journal-title":"Bioinformatics"},{"key":"278_CR19","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"278_CR20","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic acids Res. 2013;41:D955\u201361.","journal-title":"Nucleic acids Res"},{"key":"278_CR21","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151\u201361.","journal-title":"Cell"},{"key":"278_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi M, Huang FW, Jan\u00e9-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503\u20138.","journal-title":"Nature"},{"key":"278_CR23","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PloS One. 2014;9:e107468.","journal-title":"PloS One"},{"key":"278_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018;175:984\u201397.e24.","journal-title":"Cell"},{"key":"278_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411\u201320.","journal-title":"Nat Biotechnol"},{"key":"278_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002273","volume":"9","author":"KT Lynch","year":"2021","unstructured":"Lynch KT, Young SJ, Meneveau MO, Wages NA, Engelhard VH, Slingluff CL Jr, et al. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. J Immunother cancer. 2021;9:e002273.","journal-title":"J Immunother cancer"},{"key":"278_CR27","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.3390\/ijms23105384","volume":"23","author":"J T\u00edm\u00e1r","year":"2022","unstructured":"T\u00edm\u00e1r J, Lad\u00e1nyi A. Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. Int J Mol Sci. 2022;23:5384.","journal-title":"Int J Mol Sci"},{"key":"278_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022;170:256\u201384.","journal-title":"Eur J Cancer"},{"key":"278_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","volume":"82","author":"JC Stadler","year":"2022","unstructured":"Stadler JC, Belloum Y, Deitert B, Sementsov M, Heidrich I, Gebhardt C, et al. Current and Future Clinical Applications of ctDNA in Immuno-Oncology. Cancer Res. 2022;82:349\u201358.","journal-title":"Cancer Res"},{"key":"278_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17:883\u201395.","journal-title":"Lancet Oncol"},{"key":"278_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365.","journal-title":"Lancet"},{"key":"278_CR32","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.18632\/aging.103296","volume":"12","author":"Q Wang","year":"2020","unstructured":"Wang Q, Yang Y, Yang M, Li X, Chen K. High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16\/CA125 mutations. Aging. 2020;12:10827\u201343.","journal-title":"Aging"},{"key":"278_CR33","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/pharmaceutics14030590","volume":"14","author":"S Candido","year":"2022","unstructured":"Candido S, Salemi R, Piccinin S, Falzone L, Libra M. The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways. Pharmaceutics. 2022;14:590.","journal-title":"Pharmaceutics"},{"key":"278_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"key":"278_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13272","volume":"19","author":"LP Covre","year":"2020","unstructured":"Covre LP, De Maeyer RPH, Gomes DCO, Akbar AN. The role of senescent T cells in immunopathology. Aging Cell. 2020;19:e13272.","journal-title":"Aging Cell"},{"key":"278_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6:424.","journal-title":"Signal Transduct Target Ther"},{"key":"278_CR37","first-page":"Cd012974","volume":"1","author":"C Gorry","year":"2023","unstructured":"Gorry C, McCullagh L, O\u2019Donnell H, Barrett S, Schmitz S, Barry M, et al. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev. 2023;1:Cd012974.","journal-title":"Cochrane Database Syst Rev"},{"key":"278_CR38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s12016-022-08956-8","volume":"63","author":"F Gibson","year":"2022","unstructured":"Gibson F, Hanly A, Grbic N, Grunberg N, Wu M, Collard M, et al. Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. Clin Rev Allergy Immunol. 2022;63:447\u201371.","journal-title":"Clin Rev Allergy Immunol"},{"key":"278_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101156","volume":"64","author":"B Uyar","year":"2020","unstructured":"Uyar B, Palmer D, Kowald A, Murua Escobar H, Barrantes I, M\u00f6ller S, et al. Single-cell analyses of aging, inflammation and senescence. Ageing Res Rev. 2020;64:101156.","journal-title":"Ageing Res Rev"},{"key":"278_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-021-00646-9","volume":"6","author":"X Zhu","year":"2021","unstructured":"Zhu X, Chen Z, Shen W, Huang G, Sedivy JM, Wang H, et al. Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention. Signal Transduct Target Ther. 2021;6:245.","journal-title":"Signal Transduct Target Ther"},{"key":"278_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13701","volume":"21","author":"PK Barman","year":"2022","unstructured":"Barman PK, Shin JE, Lewis SA, Kang S, Wu D, Wang Y, et al. Production of MHCII-expressing classical monocytes increases during aging in mice and humans. Aging Cell. 2022;21:e13701.","journal-title":"Aging Cell"}],"container-title":["Genes & Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41435-024-00278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-024-00278-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-024-00278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T03:08:33Z","timestamp":1718334513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41435-024-00278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1038\/s41435-024-00278-3","relation":{},"ISSN":["1476-5470"],"issn-type":[{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the ethical committee in the Seventh Affiliated Hospital of Sun Yat-sen University, and informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}